View Archive »
About The Cover
The cover for issue 48 of Oncotarget features Table 3, "Clinical responses per RECIST and clinical benefit rate based on age," by Subbiah, et al.
|
|
Table of Contents
Research Papers: Immunology
|
| Rituximab as a frontline therapy for adultonset minimal change disease with nephrotic syndrome |
|
https://doi.org/10.18632/oncotarget.25612
|
| 28799-28804 |
Research Papers
|
| Exhaled breath analysis for gastric cancer diagnosis in Colombian patients |
|
https://doi.org/10.18632/oncotarget.25331
|
| 28805-28817 |
|
| Comparison of plateletalbuminbilirubin PALBI albuminbilirubin ALBI and childpugh CP score for predicting of survival in advanced hcc patients receiving radiotherapy RT |
|
https://doi.org/10.18632/oncotarget.25522
|
| 28818-28829 |
|
| A single amino acid substitution in CXCL12 confers functional selectivity at the betaarrestin level |
|
https://doi.org/10.18632/oncotarget.25533
|
| 28830-28841 |
|
| Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors |
|
https://doi.org/10.18632/oncotarget.25571
|
| 28842-28848 |
|
| Involvement of antitumor miR1243p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR1243p |
|
https://doi.org/10.18632/oncotarget.25599
|
| 28849-28865 |
|
| New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes |
|
https://doi.org/10.18632/oncotarget.25601
|
| 28866-28876 |
|
| Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma |
|
https://doi.org/10.18632/oncotarget.25608
|
| 28877-28896 |
|
| Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis |
|
https://doi.org/10.18632/oncotarget.25622
|
| 28897-28902 |
|
| Real world experience in lowdose ipilimumab in combination with PD1 blockade in advanced melanoma patients |
|
https://doi.org/10.18632/oncotarget.25627
|
| 28903-28909 |
|
| Marek’s disease virus oncoprotein Meq physically interacts with the chicken infectious anemia virusencoded apoptotic protein apoptin |
|
https://doi.org/10.18632/oncotarget.25628
|
| 28910-28920 |
|
| VATPasedependent repression of androgen receptor in prostate cancer cells |
|
https://doi.org/10.18632/oncotarget.25641
|
| 28921-28934 |
|
| Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomographyguided surgery with 64Culabeled cetuximab to treat early and latephase peritoneal dissemination in human gastrointestinal cancer xenografts |
|
https://doi.org/10.18632/oncotarget.25649
|
| 28935-28950 |
|
| MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locallyadvanced rectal adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.25652
|
| 28951-28964 |
|
| EGFR overexpression is not common in patients with head and neck cancer Cell lines are not representative for the clinical situation in this indication |
|
https://doi.org/10.18632/oncotarget.25656
|
| 28965-28975 |
|
| Targeting CREBbinding protein overrides LPS induced radioresistance in nonsmall cell lung cancer cell lines |
|
https://doi.org/10.18632/oncotarget.25665
|
| 28976-28988 |
Reviews
|
| The emergence of trophoblast cellsurface antigen 2 TROP2 as a novel cancer target |
|
https://doi.org/10.18632/oncotarget.25615
|
| 28989-29006 |
|
| Harnessing RIGI and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment |
|
https://doi.org/10.18632/oncotarget.25626
|
| 29007-29017 |
Corrections
|
| Correction: Intake of red and processed meat and risk of renal cell carcinoma: a metaanalysis of observational studies |
|
https://doi.org/10.18632/oncotarget.25715
|
| 29018-29018 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
